Is this Lupin’s next U.S. respiratory blockbuster? Generic Perforomist hits the shelves

Mumbai-headquartered Lupin Limited has launched its Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per unit-dose vial, in the U.S. market, further deepening its footprint in the competitive U.S. respiratory segment. The launch was announced on November 29, 2022, and marks the arrival of a generic version of Mylan Specialty’s Perforomist Inhalation Solution.

Formoterol Fumarate is a long-acting beta2-adrenergic agonist (LABA) used for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. In some treatment contexts, it is also used in asthma management, particularly for patients who require long-term, twice-daily bronchodilator treatment.

The U.S. Food and Drug Administration (FDA) had approved Lupin’s abbreviated new drug application (ANDA) for this formulation earlier, enabling its entry into a segment that, according to IQVIA MAT data for September 2022, is valued at an estimated $268 million in annual sales.

What is the significance of Lupin’s U.S. launch of Formoterol Fumarate Inhalation Solution?

By launching the generic version of Perforomist, Lupin has gained access to a niche yet high-value market segment within the U.S. respiratory space. Mylan’s Perforomist has long been prescribed for maintenance therapy in patients with COPD who are not adequately controlled on short-acting bronchodilators alone. With COPD incidence rising in the U.S. due to aging demographics and continued exposure to environmental pollutants, market analysts widely view this therapeutic area as a critical component of global pharma companies’ U.S. strategy.

This launch also reinforces Lupin’s ability to bring complex generic inhalation products to market—an area often characterized by high entry barriers due to the need for bioequivalence studies, device-drug integration, and stringent regulatory oversight. The 20 mcg/2 mL unit-dose vial format mirrors that of Perforomist, ensuring prescribers and patients have a familiar delivery option.

How large is the market opportunity for Lupin in the U.S. respiratory segment?

IQVIA’s September 2022 data places the trailing twelve-month sales of Formoterol Fumarate Inhalation Solution at approximately $268 million, highlighting the sizable opportunity Lupin is now entering. While the branded product has enjoyed category leadership, the introduction of generics often drives down prices, potentially expanding volume even if margins compress.

Given the chronic nature of COPD and the medication’s twice-daily dosing regimen, inhalation solutions like Formoterol Fumarate represent a consistent revenue stream. The U.S. Centers for Disease Control and Prevention (CDC) estimates that over 16 million Americans have been diagnosed with COPD, with many more potentially undiagnosed, making it one of the leading causes of disability and death in the country.

Lupin’s ability to capture a meaningful share of this segment will depend on pricing strategy, physician acceptance, payer coverage, and patient adherence—factors that the Indian pharmaceutical manufacturer has had experience navigating across its U.S. portfolio.

Why is Lupin’s respiratory portfolio gaining strategic importance?

Over the last decade, Lupin has steadily diversified its product mix beyond oral solids into inhalation therapies, ophthalmics, and injectables. Respiratory has emerged as a particularly high-priority area for the Indian pharma major, especially as global demand for inhalation drugs surged during the COVID-19 pandemic.

Lupin has previously launched other respiratory therapies in the U.S. and continues to invest in both pressurized metered dose inhalers (pMDIs) and nebulized formulations. The company’s research and development efforts in this area aim to build a robust pipeline of respiratory drugs that can meet the growing burden of chronic respiratory diseases across geographies.

The launch of the Formoterol Fumarate Inhalation Solution adds to Lupin’s growing basket of respiratory drugs that address unmet needs in asthma and COPD, therapeutic areas where treatment regimens are often lifelong and adherence is key.

What are the implications of Lupin’s Brazil acquisition for its LatAm footprint?

In a separate announcement on the same day, Lupin also confirmed that its Brazilian subsidiary, MedQuímica Indústria Farmacêutica, had acquired rights to nine drugs from BL Indústria Ótica, a subsidiary of Bausch Health Companies.

The acquisition signals Lupin’s continuing ambition to strengthen its presence in Latin America’s growing pharmaceutical markets. Brazil, in particular, has been a target geography for Lupin’s internationalization strategy, especially since its acquisition of MedQuímica in 2015.

The portfolio acquired includes a mix of prescription and over-the-counter (OTC) medicines across therapeutic categories, which are expected to enhance MedQuímica’s ability to compete more aggressively in the branded generics segment in Brazil.

According to earlier company statements, Lupin views Brazil as a strategically significant market with a robust public health system (SUS – Sistema Único de Saúde), increasing demand for generic drugs, and favorable demographics. With the Brazilian pharmaceutical market projected to grow steadily through the 2020s, further M&A-driven expansion may be on the cards.

How do analysts view Lupin’s dual expansion moves in the U.S. and Brazil?

While official analyst notes are not immediately available on the public record, market watchers often interpret simultaneous announcements in key geographies like the U.S. and Brazil as a deliberate strategy to balance revenue streams and hedge against region-specific volatility.

The launch of Formoterol Fumarate in the U.S. allows Lupin to participate in a relatively high-margin inhalation segment, while the Brazilian deal bolsters volume-led growth in a value-driven but competitive branded generics market.

Lupin has repeatedly emphasized its focus on complex generics, global respiratory markets, and differentiated delivery platforms as it attempts to recover from past regulatory headwinds and margin pressures in key markets.

By deploying a two-pronged strategy—targeting technologically complex markets like the U.S. and volume-led emerging markets like Brazil—Lupin appears to be optimizing its global footprint while minimizing overdependence on any single region or therapeutic category.

What’s next for Lupin’s global growth trajectory?

Lupin’s recent activity indicates that it is doubling down on high-value segments such as respiratory care in the U.S. while simultaneously shoring up its presence in emerging markets. As the company looks to regain investor confidence amid ongoing FDA scrutiny at some manufacturing sites, product launches like the Formoterol Fumarate Inhalation Solution help shift the focus back to operational execution.

If the Indian pharmaceutical company can scale sales of its new U.S. respiratory product while leveraging its expanded Brazil footprint, it may position itself more favorably against regional peers also vying for global respiratory market share.

Industry insiders believe that future Lupin launches will likely come from its complex generics pipeline, which includes other inhalation therapies, biosimilars, and injectables. Investors and healthcare stakeholders will be watching closely to see if Lupin can maintain regulatory compliance while expanding aggressively across both developed and emerging markets.